28 results about "Salbutamol" patented technology

The present disclosure provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. Salmeterol or a pharmaceutically acceptable salt thereof may be administered conjointly with an erythropoiesis-stimulating agent, optionally wherein the anemia is refractory to the erythropoiesis-stimulating agent. Also provided are methods of promoting differentiation of an erythroid progenitor cell toward a mature red blood cell in a patient in need thereof, comprising administering an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. The present disclosure further provides methods comprising administering salbutamol or a pharmaceutically acceptable salt thereof. Salmeterol, salbutamol, or a pharmaceutically acceptable salt thereof may be administered conjointly with other FDA-approved drugs such as luspatercept, lenalidomide, daprodustat, vadadustat, an erythropoiesis-stimulating agent (ESA), and / or a hypomethylating agent.

Disclosed is a pharmaceutical composition for inhalation comprising salbutamol or enantiomer or salt or ester thereof and a pharmaceutically acceptable green propellant. Particularly, disclosed is a pharmaceutical composition for inhalation comprising salbutamol or enantiomer or salt or ester thereof and a pharmaceutically acceptable green propellant HFA-152a and / or HFO-1234ze(E). Also disclosed processes of preparing such compositions.

Pharmaceutical aerosol formulations containing pre-micronized albuterol sulfate, high amount of green propellant trans-1,3,3,3-tetrafluoropropene (HFO-1234ze(E)), and a surfactant (polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polyethylene glycol 1000, span 85 (sorbitan trioleate), polyvinylpyrrolidone K25, or their combination) in a pressurized metered dose inhaler are described. The formulations do not use any co-solvent, i.e., they are co-solvent-free (e.g., free of ethanol, glycerol, propylene glycol, and a combination thereof). The formulations provide highly efficient delivery, through metered dose inhaler (MDI), of pre-micronized albuterol particles into the patients' respiratory tracts and have the advantages of high efficacy, improved safety, and a low global warming potential (GWP) for environmental impact.

The application discloses a microbial nano-enzyme probe, a method for detecting salbutamol and application, and comprises a salbutamol monoclonal antibody and a signal carrier, wherein the signal carrier is a yeast cell loaded with iridium oxide nanoparticles. The application firstly constructs a probe by using a yeast cell loaded with iridium oxide nanoparticles in the detection of an immunochromatographic test strip, uses [3, 3', 5, 5' tetramethylbenzidine (TMB) and hydrogen peroxide (H2O2)] as a substrate to trigger a color developing reaction, can realize high-sensitivity target detection, and the detection limit is as low as 0.012 ng / mL, which is 55 times higher than the sensitivity of a traditional gold-labeled test strip. In addition, the application has a good application prospect, can provide a universal platform for sensitive, accurate and rapid detection of food-borne stimulants, and can be successfully applied to the detection of salbutamol in pig liver and beef samples.

The application discloses a method for detecting clenbuterol based on thin layer chromatography and surface enhanced resonance Raman spectroscopy, and belongs to the technical field of food detection. The method comprises the following steps: (1) adopting thin layer chromatography to preliminarily separate the clenbuterol component from the matrix in the pig liver sample, and confirming the clenbuterol component in the pig liver sample under the ultraviolet lamp of 254 nm; (2) adding aromatic diazonium salt solution to the same Rf value of the clenbuterol component reference sample spot to generate azo compounds, and then adding a surface enhancer silver sol; (3) in-situ detecting the surface enhanced resonance Raman spectrum of the corresponding azo compound component spot, and if the surface enhanced resonance Raman spectrum of the pig liver sample solution at the same Rf value is the same as that of the reference sample solution, it is determined that the pig liver sample contains the clenbuterol component. The application has high specificity for detecting clenbuterol and salbutamol, high sensitivity, fast analysis speed, and is beneficial to fast detection of grass-roots units. The application is suitable for detecting clenbuterol.

The utility model discloses a salbutamol fluorescent quantitative detection card which comprises a detection card main shell, a test paper mounting groove is formed in the detection card main shell, a detection card end block is detachably mounted at one end of the detection card main shell, and extrusion buttons are slidably mounted on the upper surface and the lower surface of the detection card end block. A connecting spring is fixed between the two extrusion buttons, a test paper clamping groove is formed in the end face, facing the detection card main shell, of the detection card end block, and two anti-falling elastic clamping plates which are symmetrical up and down are fixedly arranged on the inner side of the test paper clamping groove. According to the utility model, by pressing the two extrusion buttons, the two extrusion plates extrude the two anti-drop elastic clamping plates, so that the anti-drop elastic clamping plates are separated from the detection card main shell, and the used test paper can be taken out from the detection card main shell by pulling the detection card end block, so that the detection test paper is convenient to replace; the use cost is reduced.

The invention belongs to the field of pharmaceutics, particularly relates to a composition containing levosalbutamol hydrochloride and ipratropium bromide as well as a preparation method and application of the composition, and overcomes the defects of a stabilizer disodium ethylene diamine tetraacetate adopted in the prior art. The invention provides a levosalbutamol hydrochloride and ipratropium bromide composition which is simpler in prescription and better in safety, can be used for treating reversible bronchospasm related to airway obstructive diseases, can jointly act on muscarinic acid and beta2 adrenergic receptors in the lung, can enhance the bronchiectasia effect, takes effect quickly, and is free of toxic and side effects. The clinical application value is very high.

The present disclosure relates to an inhalation treatment device comprising: a sensor (47) configured to detect a flow parameter of a flow in a flow path (7); a controller (18) configured to conclude at least an inhalation phase and / or an exhalation phase of the user based on the output of the sensor (47), and to repeatedly operate the actuator (6) during a period of inhalation phase and not to operate the actuator (6) during a period of exhalation phase during a single treatment time, when using a test solution of salbutamol dissolved in 0.9% sodium chloride at a concentration of 0.1% (M / V) as a liquid, the aerosol output rate of the inhalation treatment device at the first opening (8) during a single treatment time is at least 0.48 g / min at the median mass diameter of the aerosol droplet of between 4.5 [mu] m and 5.0 [mu] m, and the aerosol output rate at the second opening (8) is at least 0.48 g / min at the median mass diameter of the aerosol droplet of between 4.5 [mu] m and 5.0 [mu] m. Or at least 0.42 g / min at a mass median diameter of the aerosol droplet between 4.0 [mu] m and 4.5 [mu] m, or at least 0.29 g / min at a mass median diameter of the aerosol droplet between 3.5 [mu] m and 4.0 [mu] m, or at least 0.20 g / min at a mass median diameter of the aerosol droplet between 3.0 [mu] m and 3.5 [mu] m, or at least 0.13 g / min at a mass median diameter of the aerosol droplet between 2.5 [mu] m and 3.0 [mu] m.

Disclosed are medicinal compositions, and devices, methods and systems which use same, comprising a carrier and at least one medicinally active compound, said carrier comprising at least 1234ze(E), ethanol and polyethylene glycol.

The present invention relates to a pharmaceutical composition consisting of an active ingredient based on salbutamol (a), 1,1-difluoroethane (b), a polyethylene glycol (c) and ethanol (d).The invention also relates to the use of such a pharmaceutical composition in the treatment of respiratory disorders, to a canister comprising it as well as to a metered-dose inhaler provided with such a canister.Finally, the invention relates to the uses of this pharmaceutical composition and of this canister in a metered-dose inhaler.

Disclosed is a pharmaceutical composition comprising: an active pharmaceutical ingredient (API) comprising salbutamol; from about 85% to about 99% by weight of HFO-1234ze (E); from 1% to about 15% by weight of ethanol; and greater than 0.01% to less than 0.1% by weight of oleic acid.

The invention relates to a method for preparing (R)-salbutamol. Specifically, L-threonine and a compound 1 are taken as raw materials, a compound 2 is formed under the catalysis of L-threonine transaldolase, the compound 2 is formed into a compound 3 under the catalysis of decarboxylase, on the basis, the compound 3 is taken as a substrate, and the (R)-salbutamol is further synthesized. And the method has the characteristics of low cost of raw materials and auxiliary materials, short process steps, simplicity and convenience in operation, mild reaction conditions and environmental friendliness.

The invention provides a novel method for producing drimane aldehydes through catalysis of alcohol dehydrogenase. The method is realized by oxidizing a corresponding drimane alcohol precursor in vitro or in vivo. The invention also relates to the identification of enzymes having corresponding alcohol dehydrogenase activity from different microbial and plant sources. Further forms of the invention relate to providing corresponding coding sequences of such enzymes, recombinant vectors and recombinant host cells suitable for producing such alcohol dehydrogenases. Another form of the invention relates to the use of such dripane aldehydes obtained according to the invention as intermediates for the production of odorants, flavors or fragrances or insect / pest control ingredients.

The present disclosure provides a method of treating asthma in a subject at risk of asthma exacerbation, and a method of as-needed treatment or prevention of bronchoconstriction in a subject, and / or prevention of exacerbation in a subject with asthma, comprising administering as needed to the subject a composition comprising therapeutically effective amounts of albuterol and budesonide, wherein the composition is administered via a metered dose inhaler, wherein the method reduces risk of severe asthma exacerbation by at least about 15% as compared to administration of a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation. Also provided is a pharmaceutical composition comprising: albuterol and budesonide in the form of particles; a suspension medium comprising a hydrofluoroolefins (HFO) propellant and / or a hydrofluorocarbon propellant (HFC), and a plurality of respirable suspending particles, wherein the particles of albuterol and budesonide associate with the plurality of respirable suspending particles.

A pharmaceutical composition in the form of droplets for oral administration is disclosed. The pharmaceutical composition is an aqueous solution comprising sodium chloride in an amount of 0.6% to 3% by weight per volume, at least one active ingredient selected from naloxone, yohimbine, albuterol, epinephrine, buprenorphine, and exosomes in an amount of 0.01% to 25% by weight per volume, and having a pH from 3 to 7.5. The composition is converted into droplets with diameters of 0.5 to 5 microns using an atomizer with a vibrating mesh membrane undergoing piezoelectric vibration at a frequency of 25 to 400 kilohertz. The process involves providing the composition in a capsule, inserting the capsule into the atomizer, and activating the atomizer to produce droplets. This system provides precise, efficient, and patient-friendly oral delivery of medications.

This invention provides a highly effective antibacterial endotracheal tube and its preparation method, relating to the field of medical implant materials technology. The method includes the following steps: S1: Ofloxacin is placed in a first activating agent for a first activation treatment to obtain activated ofloxacin, which contains amide groups; S2: Salbutamol is placed in a second activating agent for a second activation treatment to obtain activated salbutamol, which contains ether groups; S3: A silicone endotracheal tube is subjected to a third activation treatment to obtain an activated silicone endotracheal tube, the surface of which contains silanol groups; S4: Activated ofloxacin and activated salbutamol are grafted onto the surface of the activated silicone endotracheal tube to obtain a highly effective antibacterial endotracheal tube. This invention, by activating ofloxacin and salbutamol separately and attaching them to the surface of the silicone endotracheal tube, endows the endotracheal tube with highly effective antibacterial properties and tracheal adaptability.

The invention discloses a method for detecting an intermediate III in a salbutamol bulk drug. The method has high system applicability, has incomparable advantages in specificity, quantitation limit, detection limit, linear range, repeatability and durability, and has high precision.

The present invention provides a composition for use in a pressurised dispensing container, the composition comprising:from 3 to 10 wt. % of a monohydric alcohol, based on the total weight of the composition;at least 85 wt. % HFA152a and / or HFO1234ze, based on the total weight of the composition; andalbuterol sulfate and / or levalbuterol tartrate.

The invention relates to a composition for treating or preventing acute attack of bronchial asthma as well as a preparation method and application of the composition. Specifically, the invention provides an aerosol inhalation composition, which contains budesonide and salbutamol or pharmaceutically acceptable salts thereof, and does not contain a metal chelating agent. The invention accidentally finds that the aerosol inhalation composition can unexpectedly reduce the generation of salbutamol R and D impurities, has high stability, increases the aerosol inhalation volume of a patient, has less aerosol residue, and is beneficial to absorption. The composition has an excellent effect of preventing and / or treating acute attack of asthma.

The application provides a high-sensitivity detection method for multi-residues of veterinary drugs in pig urine, and belongs to the technical field of detection of veterinary drug residues. The application first performs enzymatic treatment on the sample to be detected, thereby improving the detection sensitivity of salbutamol and ractopamine; then performs acid hydrolysis and derivatization treatment on the sample to be detected, thereby improving the reversed-phase chromatographic retention performance and mass spectrometry ionization efficiency of nitrofurans in the compound to be detected, improving the sensitivity, improving the polarity of the compound to be detected, thereby improving the chromatographic separation effect, effectively separating the interfering substances in the matrix, improving the anti-interference ability of the detected substance, and indirectly improving the detection sensitivity; clenbuterol, metronidazole, dimetridazole, olaquindox, chlorpromazine and chloramphenicol are mainly in free state, and are not affected by enzymatic and acid hydrolysis and derivatization during detection, can be detected together with the above-mentioned compounds to be detected, and the mass spectrometry derivatization and sensitivity detection of multi-residues of cross-class veterinary drugs are realized.

The invention belongs to the field of pharmacy, and particularly discloses a salbutamol instant tablet based on a freeze drying-microsphere embedding technology and a preparation process. The tablet comprises a porous matrix formed by freeze drying and salbutamol-loaded microspheres dispersed in the porous matrix, the microspheres are formed by ionic crosslinking of zinc hyaluronate and pullulan polysaccharide (the mass ratio is 1: 0.5-1: 3), the diameter is 20-150 microns, and the zinc ion content is 0.5-5%. And the porous matrix contains a sorbitol-povidone K30 freeze-drying protective agent (3: 1-6: 1, 8-12%). The preparation process comprises the following steps: dissolving salbutamol and zinc hyaluronate in an acetic acid buffer solution, dropwise adding a pullulan solution containing calcium ions to form microspheres, quickly freezing with liquid nitrogen, and carrying out gradient freeze drying (-35 DEG C to-15 DEG C to 10 DEG C to 25 DEG C). The tablet disintegration time is less than or equal to 8 seconds, the dissolution rate in 5 minutes is greater than or equal to 90%, the increase of related substances accelerated for 6 months is less than or equal to 0.5%, the bitterness score is less than or equal to 1.5 score, and the tablet is suitable for first aid of children asthma and exercise asthma.

The invention provides a synthesis method of salbutamol, which takes p-hydroxy benzaldehyde as an initial raw material, and salbutamol is obtained through multi-step reaction. The synthesis route is simple, the cost is low, the yield and the purity are high, aftertreatment is simple, and the method is suitable for industrial production.

The present invention relates to a transdermal composition comprising a compound selected from the group comprising formoterol, salbutamol, salmeterol, fenoterol, mixtures thereof or salts thereof, and dimethylsulfoxide. The present invention further relates to a composition comprising a compound selected from the group comprising salbutamol, clenbuterol or salts thereof, and comprising at least one of water or a monohydric alcohol.

The present invention provides a levosalbutamol hydrochloride nebulized inhalation solution composition and a preparation method thereof, belonging to the technical field of pharmaceutical preparations. The composition comprises levosalbutamol hydrochloride, a costabilizer, an osmotic pressure regulator, a pH regulator, and a solvent. Edetate disodium, gentisic acid, and sodium diacetate are used as costabilizers. The costabilizers enhance the stability of the composition and extend its storage time. Furthermore, the composition simplifies the preparation process without nitrogen filling protection, reduces the requirements for production equipment, is simple and easy to operate, and has low production costs.

The application provides a synthesis method of levalbuterol hydrochloride, which creatively takes raw material-1 (2-[benzyl(tert-butyl)amino]-1-(2,2-dimethyl-4 H -benzo[ d ][1,3]dioxin-6-yl)ethanone) as a starting material, and high-purity levalbuterol hydrochloride is prepared through reduction, separation, hydrolysis, hydrogenation debenzylization and salt formation reaction in sequence. The method has the advantages of mild reaction, simple operation, high yield, low cost and suitability for industrial production. The levalbuterol hydrochloride prepared by the method has single impurity less than 0.05% and total impurity less than 0.1%, which can effectively ensure the safety of patients in medication.

Disclosed are pharmaceutical compositions comprising a vehicle comprising at least 1234ze(E) and ethanol and at least one pharmaceutically active compound, and devices, methods, and systems using the same.

The invention discloses a preparation method of a salbutamol EP impurity N. The salbutamol EP impurity N is obtained by taking salbutamol as a raw material and carrying out dimerization reaction under an acidic condition. The method has the advantages that the salbutamol dimer can be obtained only by one step through the dimerization reaction under the acidic condition, and multi-step complex synthesis is not needed. According to the present invention, the reaction conditions are simple, the whole process is easy to operate, the technical and operation difficulty in the synthesis process is reduced, and the synthesized and identified salbutamol EP impurity N can be adopted as the impurity reference substance, can be directly applied to the quality control link in the salbutamol bulk drug production process, and can assist the improvement of the accuracy and the reliability of the bulk drug quality research.

Pressurised dispensing container (10) comprising a container for product to be dispensed, and a valve fixed to the container; wherein the valve comprises a valve stem (15), a valve body (16) and one or more seals (20, 21), the valve stem being slidable within the valve body, the one or more seals co-operating with the valve stem for regulating discharge of a fluid; wherein the valve further comprises a sealing gasket (14) for sealing the valve to the dispensing container; wherein the one or more seals is / are formed from an elastomeric composition comprising an ethylene-propylene-diene terpolymer; wherein the sealing gasket is formed from an elastomeric composition comprising an isobutylene polymer or co-polymer thereof; and wherein the container contains a formulation comprising: a propellant comprising HFO-1234ze; salbutamol and / or a salt thereof; and from 1 to 2 wt.% of a monohydric alcohol, based on the total weight of the formulation.